Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial.

Miguel Ángel Climent,Begoña Pérez-Valderrama,Begoña Mellado,Eva María Fernández Parra,Ovidio Fernández Calvo,María Ochoa de Olza,Laura Muinelo Romay,Urbano Anido,Montserrat Domenech,Susana Hernando Polo,José Ángel Arranz Arija,Cristina Caballero,María José Juan Fita,Daniel Castellano

European Journal of Cancer（2017）

引用 17|浏览21

暂无评分

摘要

•Weekly cabazitaxel instead of every 3 weeks has been tested.•Circulating tumour cells (CTCs) have been assessed.•‘Unfit’ patients could benefit with the proposed regimen.•Changes in CTCs could be useful in these cases as an early response marker.

查看译文

关键词

Cabazitaxel,Castration-resistant prostate cancer,Circulating tumour cells,Dosing schedule,Toxicity

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要